RecruitingPhase 2NCT06660732
Rilonacept in Subjects With Cardiac Sarcoidosis
Studying Sarcoidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Andrew Rosenbaum, MDMayo Clinic
- Intervention
- Rilonacept(drug)
- Enrollment
- 60 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2025 – 2027
Study locations (2)
- Johns Hopkins University, Baltimore, Maryland, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Collaborators
Johns Hopkins University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06660732 on ClinicalTrials.govOther trials for Sarcoidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07498842Corticosteroid Tapering in SarcoidosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07073963Virtual Patient Groups for Sarcoidosis Associated FatigueThe Cleveland Clinic
- RECRUITINGPHASE2NCT07159074Repurposing Tilmanocept for Cardiac SarcoidosisDuke University
- RECRUITINGPHASE2NCT06978725A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)Priovant Therapeutics, Inc.
- RECRUITINGNANCT05954507Evaluation of the Prognostic Value of PET/MRI in Cardiac SarcoidosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07384897Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung DiseaseUniversité Catholique de Louvain
- RECRUITINGNCT06510894Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose SuppressionUniversity of Pennsylvania
- RECRUITINGPHASE4NCT05841758Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary SarcoidosisHospices Civils de Lyon